Moving from an “anti-aging” paradigm toward the concept of “disease-free aging”: the role of senolytics in modern medicine
Senescent cells increase with aging and are related to the promotion of inflammation and neoplasia through the senescence-associated secretory phenotype (SASP). These cells are closely related to the biological aging process and, most importantly, to age-associated diseases, such as osteoporosis and...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Brazilian Society of Geriatrics and Gerontology
2025-01-01
|
| Series: | Geriatrics, Gerontology and Aging |
| Subjects: | |
| Online Access: | https://cdn.publisher.gn1.link/ggaging.com/pdf/v18e0000240.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590418593710080 |
|---|---|
| author | Ivan Aprahamian Andréia Pain Virgílio Garcia Moreira |
| author_facet | Ivan Aprahamian Andréia Pain Virgílio Garcia Moreira |
| author_sort | Ivan Aprahamian |
| collection | DOAJ |
| description | Senescent cells increase with aging and are related to the promotion of inflammation and neoplasia through the senescence-associated secretory phenotype (SASP). These cells are closely related to the biological aging process and, most importantly, to age-associated diseases, such as osteoporosis and osteoarthritis. Senolytics are a new drug class that kills senescent cells by targeting senescent cell anti-apoptotic pathways (SCAPs), which are biological systems that avoid cellulardestruction and host innate defenses. Senolytic therapy requires strong evidence in human trials, and dasatinib and quercetin have shown good results in phase II trials with idiopathic pulmonary fibrosis and diabetic renal disease. However, these trials are small and merely represent a proof-of-concept for these drugs. Nevertheless, this evidence calls for an overview of senescent cells and senolytics. We briefly discuss these related topics, summarizing the best evidence for clinical practitioners. |
| format | Article |
| id | doaj-art-b574079bb09d4505a831fc29a4b1355c |
| institution | Kabale University |
| issn | 2447-2123 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Brazilian Society of Geriatrics and Gerontology |
| record_format | Article |
| series | Geriatrics, Gerontology and Aging |
| spelling | doaj-art-b574079bb09d4505a831fc29a4b1355c2025-01-23T19:46:57ZengBrazilian Society of Geriatrics and GerontologyGeriatrics, Gerontology and Aging2447-21232025-01-01181510.53886/gga.e0000240_ENMoving from an “anti-aging” paradigm toward the concept of “disease-free aging”: the role of senolytics in modern medicineIvan Aprahamian0https://orcid.org/0000-0003-3806-7895Andréia Pain1https://orcid.org/0000-0002-9501-0863Virgílio Garcia Moreira2https://orcid.org/0000-0002-4932-1935Departamento de Clínica Médica, Divisão de Geriatria, Faculdade de Medicina – Jundiaí (SP), Brazil.Departamento de Clínica Médica, Divisão de Geriatria, Faculdade de Medicina – Jundiaí (SP), Brazil.Departamento de Clínica Médica, Faculdade de Ciências Médicas, Universidade Estadual do Rio de Janeiro – Rio de Janeiro (RJ), Brazil.Senescent cells increase with aging and are related to the promotion of inflammation and neoplasia through the senescence-associated secretory phenotype (SASP). These cells are closely related to the biological aging process and, most importantly, to age-associated diseases, such as osteoporosis and osteoarthritis. Senolytics are a new drug class that kills senescent cells by targeting senescent cell anti-apoptotic pathways (SCAPs), which are biological systems that avoid cellulardestruction and host innate defenses. Senolytic therapy requires strong evidence in human trials, and dasatinib and quercetin have shown good results in phase II trials with idiopathic pulmonary fibrosis and diabetic renal disease. However, these trials are small and merely represent a proof-of-concept for these drugs. Nevertheless, this evidence calls for an overview of senescent cells and senolytics. We briefly discuss these related topics, summarizing the best evidence for clinical practitioners.https://cdn.publisher.gn1.link/ggaging.com/pdf/v18e0000240.pdfagingbiologysenotherapeutics |
| spellingShingle | Ivan Aprahamian Andréia Pain Virgílio Garcia Moreira Moving from an “anti-aging” paradigm toward the concept of “disease-free aging”: the role of senolytics in modern medicine Geriatrics, Gerontology and Aging aging biology senotherapeutics |
| title | Moving from an “anti-aging” paradigm toward the concept of “disease-free aging”: the role of senolytics in modern medicine |
| title_full | Moving from an “anti-aging” paradigm toward the concept of “disease-free aging”: the role of senolytics in modern medicine |
| title_fullStr | Moving from an “anti-aging” paradigm toward the concept of “disease-free aging”: the role of senolytics in modern medicine |
| title_full_unstemmed | Moving from an “anti-aging” paradigm toward the concept of “disease-free aging”: the role of senolytics in modern medicine |
| title_short | Moving from an “anti-aging” paradigm toward the concept of “disease-free aging”: the role of senolytics in modern medicine |
| title_sort | moving from an anti aging paradigm toward the concept of disease free aging the role of senolytics in modern medicine |
| topic | aging biology senotherapeutics |
| url | https://cdn.publisher.gn1.link/ggaging.com/pdf/v18e0000240.pdf |
| work_keys_str_mv | AT ivanaprahamian movingfromanantiagingparadigmtowardtheconceptofdiseasefreeagingtheroleofsenolyticsinmodernmedicine AT andreiapain movingfromanantiagingparadigmtowardtheconceptofdiseasefreeagingtheroleofsenolyticsinmodernmedicine AT virgiliogarciamoreira movingfromanantiagingparadigmtowardtheconceptofdiseasefreeagingtheroleofsenolyticsinmodernmedicine |